Septated concha bullosa in an antrochoanal polyp patient

The term of septated concha bullosa has been described recently and it is an uncommon pneumatization anomaly of the middle turbinate. Solitary, benign soft tissue masses originating at the maxillary sinus and extending to the nasopharynx are called antrochoanal polyps. Antrochoanal polyp may be accompanied by concha bullosa. However, combination of septated concha bullosa and antrochoanal polyp has never been reported to the best of our knowledge. This paper presents a 45-year-old male patient who has a combination of septated concha bullosa and antrochoanal polyp

Choanal polyp originating from superior turbinate

Solitary, benign soft tissue masses starting at the nasal cavity and extending to the nasopharynx are termed choanal polyps. They most frequently originate in the maxillary sinus and are termed antra-choanal polyp. Cases of CP originating in the upper concha are rather rare and only one case has been reported in literature in the English language to the best of our knowledge. This paper discusses a CP case originating in the upper concha, which was treated by endoscopic surgical technique, in the light of its clinical presentation and radiological findings.

Predictors of neck metastasis in early stage oral cavity cancer

Objective: To identify the effects of clinical and histopathological parameters on neck metastasis in early-stage oral cavity cancers

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN